Article Details

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002

Retrieved on: 2021-09-27 00:22:30

Tags for this article:

Click the tags to see associated articles and topics

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002. View article details on hiswai:

Excerpt

SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up